Brokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

Foreign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...

Global markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...

In its quarterly investor presentation, Cipla listed some emerging challenges for the next two quarters.

“Assuming 10-15% market share and price discount of 25-30%, gSeretide could be a USD25-35m annual sales opportunity for Cipla,” said HSBC.

India Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...